Abe Yōan-dō Pharmaceuticals Joins Second Phase of EpiClock Co-Creation Project

Abe Yōan-dō Pharmaceuticals Engages in EpiClock Co-Creation Project Phase Two

Abe Yōan-dō Pharmaceuticals, known for its NMN supplements and skincare products, has recently announced its involvement in the second phase of the EpiClock Co-Creation Project. This innovative initiative is spearheaded by Rhelixa, which is based in Chuo City, Tokyo, and focuses on using epigenetic clock technology to assess biological age.

The primary objective of this project is to combine Abe Yōan-dō's NMN and traditional Japanese herbal-derived products with the scientific advancements of the epigenetic clock. This collaboration aims to substantiate the effects of continuous use of supplements and skincare items on biological age through rigorous scientific verification.

By visualizing "invisible youth," the company seeks to expand the prospects for personalized anti-aging care and promote a well-being-oriented lifestyle. Abe Yōan-dō Pharmaceuticals is dedicated to enhancing healthy longevity and helping individuals shine throughout their lives by merging traditional wisdom with cutting-edge science.

Insight from the CEO

The company's CEO, Tomotaka Abe, emphasizes the blend of NMN and traditional Japanese herbal ingredients as a comprehensive approach to anti-aging. NMN is capable of addressing seven to eight factors identified as hallmarks of aging. By integrating various components that support youthfulness, they aim to bolster these effects. The ultimate aspiration is to extend healthy longevity – allowing individuals to thrive both mentally and physically to the age of 120.

According to Abe, the company desires to support vibrant lives where individuals can continue to challenge themselves regardless of age. This project will facilitate the dissemination of the benefits of NMN, fostering a new paradigm of well-being for a broader audience.

Background and Future of the EpiClock Project

The EpiClock Co-Creation Project leverages a technology that analyzes DNA methylation data to present biological age, which may differ significantly from chronological age. In this second phase, Abe Yōan-dō Pharmaceuticals will collaborate with various companies that provide NMN, supplements, and skincare products to scientifically assess the changes in youthfulness before and after product usage. This evaluation is expected to provide users with new insights into their lifestyles.

The company is committed to strengthening collaborations with research institutions moving forward, focusing on the development of evidence-based products through the fusion of science and tradition, ultimately realizing sustainable well-being.